Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$80.06 USD
-1.28 (-1.57%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $80.25 +0.19 (0.24%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.06 USD
-1.28 (-1.57%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $80.25 +0.19 (0.24%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Zacks News
Ligand (LGND) Diabetes Candidate Positive in Phase II Study
by Zacks Equity Research
Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.
Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%
by Zacks Equity Research
Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data
by Arpita Dutt
Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.
Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label
by Zacks Equity Research
The European Commission approves Amgen's (AMGN) marketing application for Mimpara's pediatric formulation to heal secondary hyperparathyroidism (HPT).
Top Ranked Momentum Stocks to Buy for August 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 30th:
3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock
by Zacks Equity Research
Momentum Stock Investors Will Love Ligand Pharmaceuticals (LGND) seeing its favorable price performance both in short and long term.
Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) regulatory applications for tezacaftor/ivacaftor (Kalydeco) combination have been accepted by the FDA and EMA for review.
Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%
by Zacks Equity Research
Myovant Sciences Ltd. (MYOV) was a big mover last session, as the company saw its shares rise over 16% on the day.
Can Ligand's Captisol Deals Boost Growth in the Long Run?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
Ligand Signs Agreement with Amgen, Grants Rights to Captisol
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330
Ligand Gets Milestone Payment on Partner Drug FDA Approval
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key FDA Events to Watch Out for in Jun 2017
by Arpita Dutt
Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.
Ligand (LGND) Signs Licensing Deal with xCella Biosciences
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.
Can Ligand (LGND) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
New Strong Sell Stocks for March 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
by Zacks Equity Research
The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.
Forget Alexion, Buy these 4 Biotech Stocks Instead
by Arpita Dutt
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
Ligand (LGND) Signs Licensing Deals with Ono and Novartis
by Zacks Equity Research
Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.